|
|
||||||||
Reproductive Biology and Medicine Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA
1 Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Room 5D37, Bethesda, Maryland 20892, USA
2 Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
3 Clinical Neurocardiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA
4 Brain Tumor Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
5 Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
(Requests for offprints should be addressed to Z Zhuang; Email: zhuangp{at}mail.nih.gov)
Pheochromocytomas are catecholamine-producing tumors that can occur in the context of von HippelLindau syndrome (VHL) and multiple endocrine neoplasia type 2 (MEN2). Pheochromocytomas in these two syndromes differ in histopathological features, catecholamine metabolism, and clinical phenotype. To further investigate the nature of these differences, we compared the global protein expressions of 8 MEN2A-associated pheochromocytomas with 11 VHL-associated pheochromocytomas by two-dimensional gel electrophoresis proteomic profiling followed by sequencing and identification of differentially expressed proteins. Although both types of pheochromocytoma shared similarities in their protein expression patterns, the expression of several proteins was distinctly different between VHL- and MEN2A-associated pheochromocytomas. We identified several of these differentially expressed proteins. One of the proteins with higher expression in MEN2-associated tumors was chromogranin B, of which the differential expression was confirmed by western blot analysis. Our results expand the evidence for proteomic differences between these two tumor entities, and suggest that VHL-associated pheochromocytomas may be deficient in fundamental machinery for catecholamine storage. In light of these new findings, as well as existing evidence for differences between both types of pheochromocytomas, we propose that these tumors may have different developmental origins.
This article has been cited by other articles:
![]() |
J. Gaal, F. H. van Nederveen, Z. Erlic, E. Korpershoek, R. Oldenburg, C. C. Boedeker, U. Kontny, H. P. Neumann, W. N. M. Dinjens, and R. R. de Krijger Parasympathetic Paragangliomas Are Part of the Von Hippel-Lindau Syndrome J. Clin. Endocrinol. Metab., November 1, 2009; 94(11): 4367 - 4371. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Eisenhofer, T.-T. Huynh, A. Elkahloun, J. C. Morris, G. Bratslavsky, W. M. Linehan, Z. Zhuang, B. M. Balgley, C. S. Lee, M. Mannelli, et al. Differential expression of the regulated catecholamine secretory pathway in different hereditary forms of pheochromocytoma Am J Physiol Endocrinol Metab, November 1, 2008; 295(5): E1223 - E1233. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Weber and C. Eng Update on the Molecular Diagnosis of Endocrine Tumors: Toward -omics-Based Personalized Healthcare? J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1097 - 1104. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |